SCHEMBL18323151

SCHEMBL18323151

COc1ncncc1C(=O)Nc1ccc(F)c(C#Cc2nnc3cccc(Cl)n23)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 1/20 0.37
GPR6 P46095 2/20 0.35
GRM4 Q14833 4/20 0.35
MAPT P10636 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
BRAF P15056 2/20 0.34
KCNQ3 O43525 1/20 0.33
KCNQ2 O43526 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
FGFR1 P11362 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP3A5 P20815 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR4 P22455 1/20 0.33
FGFR3 P22607 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907263 0.91 KIT (0.40) MAP3K5
SCHEMBL15907265 0.82 GPR6 (0.38) MAP3K5GPR6GRM4KCNQ3KCNQ2
SCHEMBL15907251 0.75 ALDH1A1 (0.43) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL18323152 0.74 GRM4 (0.36) GRM4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL18323134 0.74 BCAT2 (0.42) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL15907279 0.69 MAP3K5 (0.39) MAP3K5GPR6MALT1
SCHEMBL15907208 0.68 BRAF (0.41) MAP3K5GRM4MAPTNPC1RAB9A
SCHEMBL15907202 0.67 MEN1 (0.50) MAP3K5MAPTNPC1RAB9A
SCHEMBL30962654 0.65 PDE4D (0.49) MAP3K5
SCHEMBL15907249 0.65 KIT (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed